JP2010505802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010505802A5 JP2010505802A5 JP2009530926A JP2009530926A JP2010505802A5 JP 2010505802 A5 JP2010505802 A5 JP 2010505802A5 JP 2009530926 A JP2009530926 A JP 2009530926A JP 2009530926 A JP2009530926 A JP 2009530926A JP 2010505802 A5 JP2010505802 A5 JP 2010505802A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydroxyamino
- alkyl
- optionally substituted
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 N-methylpiperidin-4-yl Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000002843 carboxylic acid group Chemical group 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004185 ester group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 1
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 102000013392 Carboxylesterase Human genes 0.000 claims 1
- 108010051152 Carboxylesterase Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims 1
- 235000008206 alpha-amino acids Nutrition 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000006302 indol-3-yl methyl group Chemical group [H]N1C([H])=C(C2=C([H])C([H])=C([H])C([H])=C12)C([H])([H])* 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0619753.7A GB0619753D0 (en) | 2006-10-06 | 2006-10-06 | Enzyme inhibitors |
| GB0619753.7 | 2006-10-06 | ||
| PCT/GB2007/003504 WO2008040934A1 (en) | 2006-10-06 | 2007-09-14 | Hdac inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010505802A JP2010505802A (ja) | 2010-02-25 |
| JP2010505802A5 true JP2010505802A5 (enExample) | 2010-10-28 |
| JP5395668B2 JP5395668B2 (ja) | 2014-01-22 |
Family
ID=37454078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530926A Expired - Fee Related JP5395668B2 (ja) | 2006-10-06 | 2007-09-14 | Ｈｄａｃ阻害剤 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US8637547B2 (enExample) |
| EP (2) | EP2069291B1 (enExample) |
| JP (1) | JP5395668B2 (enExample) |
| KR (1) | KR101570136B1 (enExample) |
| CN (2) | CN104151200B (enExample) |
| AU (1) | AU2007304022B2 (enExample) |
| BR (1) | BRPI0719204A2 (enExample) |
| CA (1) | CA2665428C (enExample) |
| CY (1) | CY1118881T1 (enExample) |
| DK (1) | DK2295410T3 (enExample) |
| EA (1) | EA017074B1 (enExample) |
| ES (1) | ES2626293T3 (enExample) |
| GB (1) | GB0619753D0 (enExample) |
| HU (1) | HUE033229T2 (enExample) |
| IL (1) | IL197752A0 (enExample) |
| LT (1) | LT2295410T (enExample) |
| MX (1) | MX2009003515A (enExample) |
| NZ (1) | NZ576058A (enExample) |
| PL (1) | PL2295410T3 (enExample) |
| PT (1) | PT2295410T (enExample) |
| SI (1) | SI2295410T1 (enExample) |
| WO (1) | WO2008040934A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| SG171690A1 (en) | 2005-03-22 | 2011-06-29 | Harvard College | Treatment of protein degradation disorders |
| CA2607020C (en) * | 2005-05-05 | 2015-01-13 | Chroma Therapeutics Ltd. | Alpha amino acid ester-drug conjugates hydrolysable by carboxylesterases |
| GB0509225D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
| EP1991247B1 (en) | 2006-02-14 | 2015-10-14 | President and Fellows of Harvard College | Bifunctional histone deacetylase inhibitors |
| AU2007248656B2 (en) | 2006-05-03 | 2013-04-04 | Dana-Farber Cancer Institute, Inc. | Histone deacetylase and tubulin deacetylase inhibitors |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| EA017198B1 (ru) * | 2006-10-30 | 2012-10-30 | Хрома Терапьютикс Лтд. | Гидроксаматы в качестве ингибиторов гистон-деацетилазы |
| GB0803747D0 (en) | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
| EP2321264B1 (en) | 2008-07-23 | 2016-05-04 | President and Fellows of Harvard College | Deacetylase inhibitors and uses thereof |
| DE102008062826A1 (de) | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
| GB0903480D0 (en) * | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
| WO2011019393A2 (en) * | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
| US20110053925A1 (en) * | 2009-08-28 | 2011-03-03 | Novartis Ag | Hydroxamate-Based Inhibitors of Deacetylases |
| WO2011113013A2 (en) | 2010-03-11 | 2011-09-15 | Hemaquest Pharmaceuticals, Inc. | Methods and compositions for treating viral or virally-induced conditions |
| GB201009853D0 (en) | 2010-06-11 | 2010-07-21 | Chroma Therapeutics Ltd | HSP90 inhibitors |
| WO2012025701A1 (en) | 2010-08-25 | 2012-03-01 | Chroma Therapeutics Ltd. | Alpha, alpha - di substituted glycine ester derivatives and their use as hdac inhibitors |
| WO2012025155A1 (en) * | 2010-08-26 | 2012-03-01 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases |
| CA2807738A1 (en) * | 2010-08-27 | 2012-03-01 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases |
| CN101967113B (zh) * | 2010-09-14 | 2012-08-22 | 北京欧凯纳斯科技有限公司 | 3-Alloc胺基-3-（3-硝基-4-氟苯基）丙酸及其制备方法 |
| CN101962349B (zh) * | 2010-09-15 | 2012-08-22 | 北京欧凯纳斯科技有限公司 | 3-Boc胺基-3-（3-硝基-4-氟苯基）丙酸及其制备方法 |
| CN101985432B (zh) * | 2010-09-15 | 2012-02-22 | 北京欧凯纳斯科技有限公司 | 3-Fmoc胺基-3-（3-硝基-4-氟苯基）丙酸及其制备方法 |
| CN102532006A (zh) * | 2012-01-31 | 2012-07-04 | 江西华士药业有限公司 | 治疗（类）风湿关节炎药物关键中间体6-甲基吡啶-3-甲醛的制备方法 |
| CA2868302A1 (en) | 2012-03-23 | 2013-09-26 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| KR101781922B1 (ko) | 2012-04-10 | 2017-09-26 | 안지 파마슈티컬 코퍼레이션 리미티드 | 히스톤 탈아세틸효소(hdacs) 억제제 |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| GB201211310D0 (en) | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
| AP3919A (en) | 2012-06-26 | 2016-11-30 | Bayer Pharma AG | N-[4-(quinolin-4-yloxy) cyclohexyl (methyl)](hetero) arylcarboxamides as androgen receptor antagonist, production and use thereof as medicinal products |
| ES2635240T3 (es) | 2012-10-17 | 2017-10-03 | Macrophage Pharma Limited | N-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oxopiridin-1(2H)-il]-3,5-difluorofenil}etil]-L-alaninato de terc-butilo o una sal, hidrato o solvato del mismo |
| CN103172540B (zh) * | 2013-03-18 | 2015-07-01 | 潍坊博创国际生物医药研究院 | 苯甘氨酸类组蛋白去乙酰酶抑制剂及其制备方法和应用 |
| BR112017019453A2 (pt) | 2015-03-13 | 2018-05-15 | Forma Therapeutics Inc | compostos e composições de alfa-cinamida como inibidores de hdac8 |
| CN105646297B (zh) * | 2015-09-06 | 2017-12-29 | 杨东 | 一种生产贝利司他中间体的工艺方法 |
| CN106496071B (zh) * | 2015-09-07 | 2018-07-31 | 上海医药工业研究院 | 肉桂酰胺类化合物、其盐、中间体、制备方法及应用 |
| MX2018007441A (es) | 2015-12-18 | 2018-11-09 | Procter & Gamble | Sintesis de derivados de ester de ciclohexano utiles como agentes de percepcion en productos de consumo. |
| WO2017216297A1 (en) | 2016-06-16 | 2017-12-21 | Glaxosmithkline Intellectual Property Development Limited | Dosage regimen |
| CN109715173A (zh) | 2016-07-15 | 2019-05-03 | 维拉克塔治疗公司 | 供基于nk细胞的疗法使用的hdac抑制剂 |
| ES2915827T3 (es) | 2017-05-16 | 2022-06-27 | Annji Pharm Co Ltd | Inhibidores de las histonas de acetilasas (HDACs) |
| GB201713975D0 (en) | 2017-08-31 | 2017-10-18 | Macrophage Pharma Ltd | Medical use |
| AU2019232437A1 (en) | 2018-03-07 | 2020-10-08 | Bayer Aktiengesellschaft | Identification and use of ERK5 inhibitors |
| CN212123220U (zh) * | 2019-05-17 | 2020-12-11 | 依机国际有限公司 | 快速滑出式户外工具袋 |
| EP3972963A1 (en) | 2019-05-21 | 2022-03-30 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
| PH12021552997A1 (en) | 2019-05-31 | 2023-08-14 | Viracta Subsidiary Inc | Methods of treating virally associated cancers with histone deacetylase inhibitors |
| KR20230104109A (ko) | 2020-06-08 | 2023-07-07 | 안지 파마슈티컬 코퍼레이션 리미티드 | 선택적 hdac6 억제제로서 유용한 퀴나졸린 유도체 |
| KR20220134744A (ko) * | 2021-03-26 | 2022-10-05 | 주식회사 종근당 | 다발성 경화증의 예방 또는 치료를 위한 조성물 |
| CN113582911B (zh) * | 2021-08-12 | 2024-03-12 | 山东大学 | 多靶点多奈哌齐-异羟肟酸型化合物及其制备方法和应用 |
| KR20240086748A (ko) | 2022-11-29 | 2024-06-19 | 숙명여자대학교산학협력단 | Ent-7β-하이드록시-15-옥소카우르-16-엔-18-일 아세테이트를 유효성분으로 포함하는 골질환의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1099355B (it) | 1978-10-12 | 1985-09-18 | Sclavo Inst Sieroterapeut | Composizione adatta alla determinazione in cinetica del glucosio |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5783593A (en) | 1993-11-04 | 1998-07-21 | Abbott Laboratories | Inhibitors of squalene synthetase and protein farnesyltransferase |
| YU22402A (sh) | 1999-09-08 | 2006-01-16 | Sloan-Kettering Institute For Cancer Research | Nova klasa agenasa za citodiferencijaciju i inhibitora histon deacetilaze, i postupci za njihovu upotrebu |
| JP2003514904A (ja) | 1999-11-23 | 2003-04-22 | メチルジーン インコーポレイテッド | ヒストン脱アセチル酵素の抑制剤 |
| GB0003476D0 (en) | 2000-02-16 | 2000-04-05 | British Biotech Pharm | Acetal Hydroxylamine compounds |
| DE60143520D1 (de) | 2000-03-24 | 2011-01-05 | Methylgene Inc | Inhibitoren der histon-deacetylase |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| ATE310719T1 (de) | 2000-09-29 | 2005-12-15 | Topotarget Uk Ltd | Carbaminsäurederivate enthaltend eine amidgruppe als hdac-inhibitoren |
| GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| AU9013101A (en) | 2000-09-29 | 2002-04-22 | Prolifix Ltd | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors |
| JP2004520421A (ja) | 2001-01-12 | 2004-07-08 | メチルジーン インコーポレイテッド | ヒストンデアセチラーゼ−４を特異的に抑制する方法 |
| US6784173B2 (en) | 2001-06-15 | 2004-08-31 | Hoffmann-La Roche Inc. | Aromatic dicarboxylic acid derivatives |
| CA2473505A1 (en) | 2002-02-07 | 2003-08-14 | Ellen M. Leahy | Novel bicyclic hydroxamates as inhibitors of histone deacetylase |
| EP1485354B1 (en) | 2002-03-13 | 2008-05-28 | Janssen Pharmaceutica N.V. | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
| JP4725944B2 (ja) | 2002-03-13 | 2011-07-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼの阻害剤 |
| BR0307607A (pt) | 2002-03-13 | 2004-12-21 | Janssen Pharmaceutica Nv | Derivados de carbonilamino como inibidores de histona desacetilase |
| CA2476586C (en) | 2002-03-13 | 2011-11-01 | Janssen Pharmaceutica N.V. | Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
| BR0308908A (pt) | 2002-04-03 | 2005-01-04 | Topotarget Uk Ltd | Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| GB0209715D0 (en) | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| CA2494114A1 (en) | 2002-08-02 | 2004-02-12 | Argenta Discovery Limited | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| JP2005537920A (ja) | 2002-09-04 | 2005-12-15 | バイオラブ、インコーポレーテッド | 逆浸透メンブランの消毒 |
| US7221775B2 (en) | 2002-11-12 | 2007-05-22 | Intellivid Corporation | Method and apparatus for computerized image background analysis |
| US7135493B2 (en) * | 2003-01-13 | 2006-11-14 | Astellas Pharma Inc. | HDAC inhibitor |
| AU2004215624B2 (en) | 2003-02-25 | 2011-06-02 | Topotarget Uk Limited | Hydroxamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors |
| AU2004230889B2 (en) | 2003-04-07 | 2008-03-13 | Pharmacyclics Llc | Hydroxamates as therapeutic agents |
| WO2004110989A1 (en) | 2003-05-14 | 2004-12-23 | Bayer Pharmaceuticals Corporation | N-hydroxy-7-(arylamino)heptanamide derivatives useful for treating hyper-proliferative disorders |
| CA2531661C (en) | 2003-07-07 | 2013-03-12 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| WO2005004861A1 (en) | 2003-07-15 | 2005-01-20 | Korea Research Institute Of Bioscience And Biotechnology | A use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same |
| WO2005014588A1 (en) | 2003-08-01 | 2005-02-17 | Argenta Discovery Limited | Substituted thienyl-hydroxamic acids having histone deacetylase activity |
| US20060270730A1 (en) | 2003-08-07 | 2006-11-30 | Andreas Katopodis | Histone deacetylase inhibitors as immunosuppressants |
| CA2535350A1 (en) | 2003-08-20 | 2005-03-03 | Axys Pharmaceuticals, Inc. | Acetylene derivatives as inhibitors of histone deacetylase |
| RU2356547C2 (ru) | 2003-08-26 | 2009-05-27 | Мерк ЭйчДиЭйСи Рисерч ЛЛС | Способы лечения рака с использованием ингибиторов hdac |
| US7781595B2 (en) | 2003-09-22 | 2010-08-24 | S*Bio Pte Ltd. | Benzimidazole derivatives: preparation and pharmaceutical applications |
| WO2005030705A1 (en) | 2003-09-24 | 2005-04-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| CZ2004770A3 (cs) | 2004-06-29 | 2006-02-15 | Pavelka@Miloslav | Zpusob detekce únavy operátora ze svalové cinnosti a zarízení k provádení tohoto zpusobu |
| JP4946861B2 (ja) * | 2004-08-09 | 2012-06-06 | アステラス製薬株式会社 | ヒストンデアセチラーゼ（ｈｄａｃ）の阻害活性を有するヒドロキシアミド化合物 |
| GB0509223D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| CA2607020C (en) | 2005-05-05 | 2015-01-13 | Chroma Therapeutics Ltd. | Alpha amino acid ester-drug conjugates hydrolysable by carboxylesterases |
| GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| JP5047168B2 (ja) * | 2005-06-23 | 2012-10-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストン・デアセチラーゼの新インヒビターとしてのイミダゾリノン及びヒダントイン誘導体 |
| GB0608821D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | DHFR enzyme inhibitors |
| EP2013175B9 (en) | 2006-05-04 | 2020-11-11 | Macrophage Pharma Limited | p38 MAP KINASE INHIBITORS |
| GB0608823D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of P13 kinase |
| GB0608837D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of MAP kinase |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| GB0621203D0 (en) | 2006-10-25 | 2006-12-06 | Chroma Therapeutics Ltd | PLK inhibitors |
| CA2665736A1 (en) | 2006-10-25 | 2008-05-02 | Chroma Therapeutics Ltd. | Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer |
| EA017198B1 (ru) | 2006-10-30 | 2012-10-30 | Хрома Терапьютикс Лтд. | Гидроксаматы в качестве ингибиторов гистон-деацетилазы |
| ATE524454T1 (de) | 2006-11-01 | 2011-09-15 | Chroma Therapeutics Ltd | Inhibitoren von ikk-beta serinthreoninproteinkinase |
| EA200900616A1 (ru) | 2006-11-01 | 2010-04-30 | Хрома Терапьютикс Лтд. | Ингибиторы ikk-бета серин-треонин протеинкиназы |
| GB0622084D0 (en) | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
-
2006
- 2006-10-06 GB GBGB0619753.7A patent/GB0619753D0/en not_active Ceased
-
2007
- 2007-09-14 EP EP07804290.0A patent/EP2069291B1/en not_active Not-in-force
- 2007-09-14 HU HUE10195563A patent/HUE033229T2/hu unknown
- 2007-09-14 ES ES10195563.1T patent/ES2626293T3/es active Active
- 2007-09-14 PL PL10195563T patent/PL2295410T3/pl unknown
- 2007-09-14 CA CA2665428A patent/CA2665428C/en not_active Expired - Fee Related
- 2007-09-14 EP EP10195563.1A patent/EP2295410B1/en not_active Not-in-force
- 2007-09-14 JP JP2009530926A patent/JP5395668B2/ja not_active Expired - Fee Related
- 2007-09-14 SI SI200731922A patent/SI2295410T1/sl unknown
- 2007-09-14 US US12/443,096 patent/US8637547B2/en not_active Expired - Fee Related
- 2007-09-14 KR KR1020097009318A patent/KR101570136B1/ko not_active Expired - Fee Related
- 2007-09-14 AU AU2007304022A patent/AU2007304022B2/en not_active Ceased
- 2007-09-14 EA EA200900519A patent/EA017074B1/ru not_active IP Right Cessation
- 2007-09-14 CN CN201410312767.8A patent/CN104151200B/zh not_active Expired - Fee Related
- 2007-09-14 NZ NZ576058A patent/NZ576058A/en not_active IP Right Cessation
- 2007-09-14 WO PCT/GB2007/003504 patent/WO2008040934A1/en not_active Ceased
- 2007-09-14 MX MX2009003515A patent/MX2009003515A/es active IP Right Grant
- 2007-09-14 LT LTEP10195563.1T patent/LT2295410T/lt unknown
- 2007-09-14 PT PT101955631T patent/PT2295410T/pt unknown
- 2007-09-14 CN CN200780037335.9A patent/CN101528677B/zh not_active Expired - Fee Related
- 2007-09-14 DK DK10195563.1T patent/DK2295410T3/en active
- 2007-09-14 BR BRPI0719204-5A2A patent/BRPI0719204A2/pt not_active IP Right Cessation
-
2009
- 2009-03-23 IL IL197752A patent/IL197752A0/en active IP Right Grant
-
2013
- 2013-03-14 US US13/803,258 patent/US20130197042A1/en not_active Abandoned
-
2014
- 2014-07-07 US US14/324,510 patent/US9273003B2/en not_active Expired - Fee Related
-
2016
- 2016-01-22 US US15/004,039 patent/US9725407B2/en not_active Expired - Fee Related
-
2017
- 2017-05-05 CY CY20171100489T patent/CY1118881T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505802A5 (enExample) | ||
| JP2009535387A5 (enExample) | ||
| JP2010507639A5 (enExample) | ||
| JP2008540389A5 (enExample) | ||
| US8569319B2 (en) | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities | |
| US8912182B2 (en) | Viral polymerase inhibitors | |
| JP2009535385A5 (enExample) | ||
| JP2008503484A5 (enExample) | ||
| KR920018022A (ko) | 신규 인돌 유도체, 그 제조방법 및 그를 함유하는 의약 생성물 | |
| JP2009533351A5 (enExample) | ||
| JP2010508336A5 (enExample) | ||
| JP2017528467A5 (enExample) | ||
| JP2012516896A5 (enExample) | ||
| JP2007532651A5 (enExample) | ||
| NZ601794A (en) | Di - substituted pyridine derivatives as anticancers | |
| SG166019A1 (en) | Quinoline derivatives and use thereof as mycobacterial inhibitors | |
| JP2013523896A5 (enExample) | ||
| PE20100256A1 (es) | Compuestos de ester boronato y composiciones farmaceuticas de los mismos | |
| JP2007517035A5 (enExample) | ||
| JP2007534695A5 (enExample) | ||
| JP2011527334A5 (enExample) | ||
| JP2018531987A5 (enExample) | ||
| JP2013542980A5 (enExample) | ||
| JP2011513410A5 (enExample) | ||
| JP2014526250A5 (enExample) |